Archil Jaliashvili/LinkedIn
Oct 11, 2026, 14:54
Archil Jaliashvili: NHSBT Highlights Persistent Gaps in Matched Blood for Sickle Cell Patients
Archil Jaliashvili, Co-Chief Executive Officer at GeoBio Pharm, Biotech Executive, Strategic Partner of BHOC and Precision Oxygen Therapeutics, shared a post on X:
“NHSBT reports that only around half of the matched blood demand for patients with sickle cell on regular transfusions can currently be met.
This is a compatibility challenge, not simply a shortage of units.
Our analysis.”
Other posts featuring Archil Jaliashvili on Hemostasis Today.
-
Oct 11, 2026, 14:46Sebastien Lobet: Physiotherapy and Joint Health Across the Spectrum of Bleeding Disorders
-
Oct 11, 2026, 14:38Vandana Puri: Heme Next Showcases the Future of Hematology
-
Oct 11, 2026, 14:3810 Posts Not to Miss This Week
-
Oct 11, 2026, 14:29Mohamed Magdy: Essential Thrombocythemia Summary
-
Oct 11, 2026, 14:28Mavis Agnes Kisakye: Expanding Access to Life-Saving Treatment for Bleeding Disorders
-
Oct 11, 2026, 14:18Amber Paratore Sanchez: A Novel Double-Draw Approach to Apheresis Access
-
Oct 11, 2026, 14:09Joseph Sci Borg: The Haemoglobin Switch as a Programmable Biological Transition
-
Oct 11, 2026, 14:07Robert Sidonio։ Bleeding Care for Women and Girls With Hemophilia
-
Oct 11, 2026, 13:58Jose M. Adrover: Postdoctoral Fellowship on Neutrophils and Cancer-Associated Thrombosis